This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through March 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
5 Small Drug Stocks to Buy as Sector Recovery Gains Strength
by Kinjel Shah
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, CPRX, TBPH, RLMD and AVTX may prove to be good additions to one's portfolio.
INDVPositive Net Change CPRXPositive Net Change TBPHNegative Net Change RLMDPositive Net Change AVTXNegative Net Change
biotechs pharmaceuticals
LLY Stock Up on GLP-1 Pill Approval: Can it Outpace NVO's Wegovy Pill?
by Ahan Chakraborty
Eli Lilly stock gains on FDA nod for oral obesity drug Foundayo, expanding its portfolio and patient access, setting up a fresh showdown with Novo Nordisk in the GLP-1 market.
NVONegative Net Change LLYPositive Net Change VKTXPositive Net Change GPCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Kodiak Q4 Loss Wider Than Expected, Pipeline Development in Focus
by Zacks Equity Research
KOD posts wider Q4 loss. However, its pipeline advances, with strong phase III data for Zenkuda driving accelerated regulatory plans.
CPRXPositive Net Change ANIPPositive Net Change KODPositive Net Change INDVPositive Net Change
biotechs
SRRK Stock Jumps on Resubmission of FDA Filing for SMA Drug
by Zacks Equity Research
Scholar Rock stock jumps 14% after it resubmits its FDA filing for SMA drug apitegromab, revives approval hopes and sets up a potential September 2026 decision.
NVSPositive Net Change BIIBNegative Net Change RHHBYPositive Net Change SRRKNegative Net Change
biotechs medical pharmaceuticals
AGIO Rises on Mitapivat Progress Toward Accelerated Approval in SCD
by Zacks Equity Research
Agios Pharmaceuticals jumps 14% as it moves toward accelerated FDA approval for mitapivat in sickle cell disease after key regulatory feedback.
CPRXPositive Net Change AGIONegative Net Change ANIPPositive Net Change INDVPositive Net Change
biotechs
AZN Posts Data From Hypophosphatasia Program on Efzimfotase Alfa
by Zacks Equity Research
AstraZeneca reports phase III data showing efzimfotase alfa improves bone health in children with HPP, with mixed adult results and an overall favorable safety profile.
AZNPositive Net Change PRTANegative Net Change ANIPPositive Net Change LQDAPositive Net Change
biotechs
Will Lead Drug Asceniv Fuel ADMA's Top-Line Growth in 2026?
by Ekta Bagri
ADMA rides on surging Asceniv demand, expanding payer coverage, and stronger plasma supply deals to drive rapid revenue growth through 2027.
GRFSNegative Net Change ADMAPositive Net Change TAKNegative Net Change
biotechnology biotechs medical pharmaceuticals
NVO Launches Wegovy Subscription Plan, Boosts Access, Stock Up
by Zacks Equity Research
Novo Nordisk stock jumps after launching a Wegovy subscription plan to cut costs, expand telehealth access and improve treatment adherence for sustained obesity care.
NVONegative Net Change LLYPositive Net Change CPRXPositive Net Change ADMAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Biogen to Acquire Apellis for $5.6B to Strengthen Immunology Portfolio
by Zacks Equity Research
BIIB's $5.6B offer to acquire APLS is set to add two key immunology drugs, boosting near-term revenues and strengthening its push into high-growth rare disease markets.
BIIBNegative Net Change CPRXPositive Net Change ADMAPositive Net Change APLSNegative Net Change
biotechnology biotechs immuno-therapy medical pharmaceuticals
LLY to Buy Neuroscience Biotech Centessa Pharmaceuticals in $7.8B Deal
by Zacks Equity Research
Lilly is set to acquire Centessa for up to $7.8B, adds sleep disorder drugs and advances its push to diversify beyond obesity and diabetes treatments.
BIIBNegative Net Change LLYPositive Net Change GILDPositive Net Change CNTAPositive Net Change
biotechs medical pharmaceuticals